This company is no longer active
Kintara Therapeutics (KTRA) Stock Overview
A clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
KTRA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Kintara Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.54 |
| 52 Week High | US$160.51 |
| 52 Week Low | US$2.84 |
| Beta | 0.81 |
| 1 Month Change | 12.72% |
| 3 Month Change | -14.56% |
| 1 Year Change | -94.98% |
| 3 Year Change | -99.54% |
| 5 Year Change | -99.23% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Kintara soars 66% on pausing breast cancer study, to use cash for brain cancer trial
Oct 19Kintara Therapeutics GAAP EPS of -$0.52
Sep 27Kintara Therapeutics rallies after $20M stock purchase deal with Lincoln Park Capital Fund
Aug 03Kintara Therapeutics (NASDAQ:KTRA) Will Have To Spend Its Cash Wisely
Apr 12
Shareholder Returns
| KTRA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 22.2% | -0.5% | -0.3% |
| 1Y | -95.0% | 25.4% | 14.5% |
Return vs Industry: KTRA underperformed the US Biotechs industry which returned 26.7% over the past year.
Return vs Market: KTRA underperformed the US Market which returned 35.4% over the past year.
Price Volatility
| KTRA volatility | |
|---|---|
| KTRA Average Weekly Movement | 14.5% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: KTRA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: KTRA's weekly volatility has decreased from 25% to 15% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 1 | Robert Hoffman | www.kintara.com |
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd.
Kintara Therapeutics, Inc. Fundamentals Summary
| KTRA fundamental statistics | |
|---|---|
| Market cap | US$12.80m |
| Earnings (TTM) | -US$8.50m |
| Revenue (TTM) | n/a |
Is KTRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KTRA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$8.50m |
| Earnings | -US$8.50m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.15 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did KTRA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/10/17 22:37 |
| End of Day Share Price | 2024/10/17 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kintara Therapeutics, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason McCarthy | Maxim Group |